Idenix shares soar on positive hep C study data

Shares of Idenix Pharmaceuticals surged this morning after the company reported positive results from a mid-stage study of a combination therapy for the genotype-1 strain of the hepatitis C virus. The triple drug combo included Idenix's lead drug candidate--valopicitabine (NM283)--pegylated interferon and ribavirin compared to pegylated interferon and ribavirin, the standard of care for hep C. The study demonstrated that the drug was well tolerated and produced no pharmacokinetic or pharmacodynamic drug-drug interaction between valopicitabine and ribavirin. That was welcome news to investors, who pushed up the company's stock price by 20 percent in pre-market trading.

- here's the report from StreetInsider 
- check out the release

Related Articles:
Idenix hep C therapy misses endpoints in two trials. Report
The best (and worst) biotech stocks of 2006. Report
Idenix, Novartis hepatitis drug meets trial goal. Report
Idenix CFO resigns. Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.